Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Journal of Kerman University of Medical Sciences. 2008; 15 (1): 1-7
in Persian | IMEMR | ID: emr-100438

ABSTRACT

Post transplant erythrocytosis [PTE], defined as a hematocrit level of above 51 percent, is a multifactorial condition common in renal transplant recipients. Traditional therapies include repeated phlebotomies, bilateral native nephrectomies, and anticoagulant therapy. The aim of this study was to evaluate the efficacy of ACE inhibitor on PTE. This analytic outcome study was done on all transplant patients referred to Shaid Rahnemoon hospital [Yazd, Iran]. Hematocrit [HCT] and hemoglobin were assessed in two blood samples taking from the patients. Patients with HCT >51 were selected and studied for other causes of polycythemia. Not finding other causes, the patients were diagnosed as PTE and received Enalapril tab [5 mg /daily]. Blood pressure, HCT and Hb of these patients were recorded during next 3 months [30, 60, 90th post-treatment days]. Among 126 referred patients, 47 patients had erythrocytosis [37 males [86%] and 6 females [14%]] that shows a higher prevalence in comparison with other studies. All patients responded to Enalapril treatment. Before treatment, mean hemoglobin and hematocrit were 18.35 +/- 0.59 gr/l and 55.96 +/- 1.90mm respectively, while after 3 months treatment with Enalapril, hemoglobin and hematocrit decreased to 16.7 +/- 0.5 mg/l and 48.73 +/- 1.42 mm respectively. Enalapril is an effective treatment of PTE and can prevent the need for phlebotomy or nephrectomy in these patients


Subject(s)
Humans , Male , Female , Polycythemia/drug therapy , Enalapril , Hematocrit , Phlebotomy , Nephrectomy
2.
Bol. Hosp. San Juan de Dios ; 53(5): 274-279, sept.-oct. 2006. tab, graf
Article in Spanish | LILACS | ID: lil-449876

ABSTRACT

Introducción: La eritrocitosis post transplante renal, definida por un hematocrito mayor de 51 por ciento en dos o más mediciones, es una complicación frecuente en pacientes sometidos a transplante renal. En ella, el enalapril ha demostrado ser un tratamiento efectivo. Objetivo: evaluar la eficacia y seguridad del enalapril en el manejo de la eritrocitosis post transplante renal en el Departamento de Nefrología del hospital San Juan de Dios. Material y Métodos: se revisaron las fichas de 13 pacientes transplantados entre Enero de 1998 y Marzo de 2006 en los que se diagnóstico eritrocitosis post transplante y en tratamiento actual con enalapril, evaluándose: hematocrito, presión arterial y efectos colaterales del tratamiento a lo largo del tiempo. Resultados: el hematocrito promedio pre tratamiento fue de 52,2 por ciento y a las ocho semanas de iniciada la terapia disminuyó a 47,5 por ciento, manteniéndose en el tiempo. La función renal, medida por creatininemia promedio, pre tratamiento fue de 1,43 mg*/dl a las ocho semanas de tratamiento fue de 1,44 mg/dl, continuando sin variaciones significativas durante el seguimiento. La presión arterial media promedio de los pacientes fue de 108 mmHg previo al inicio de la administración de enalapril y a las ocho semanas de tratamiento fue de 105 mmHg. Conclusiones: este estudio confirma las publicaciones anteriores acerca de la eficacia del enalapril en el manejo de la eritrocitosis post-transplante pero se necesita mantener un control permanente de los enfermos en tratamiento para garantizar la seguridad de la terapia.


Subject(s)
Male , Adolescent , Adult , Humans , Female , Middle Aged , Enalapril/therapeutic use , Polycythemia/drug therapy , Kidney Transplantation/adverse effects , Follow-Up Studies , Retrospective Studies
3.
Rev. méd. Chile ; 128(2): 211-2, feb. 2000. graf
Article in Spanish | LILACS | ID: lil-258120

ABSTRACT

A 35 years old male is presented. Eight months after receiving a renal allograft his hypertension worsened and his packed red cell volume raised to 53.7 percent. Enalapril was started and a 500 ml phlebotomy was performed. In three occasions packed red cell volumes decreased excessively and enalapril was discontinued. Finally, the drug was replaced with losartan, normalizing blood pressure values and stabilizing packed red cell volumes. This case illustrates the different reductions in packed red cell volumes induced by enalapril and losartan. These differences could have a therapeutic relevance


Subject(s)
Humans , Male , Adult , Polycythemia/drug therapy , Receptors, Angiotensin/antagonists & inhibitors , Peptidyl-Dipeptidase A/administration & dosage , Kidney Transplantation/immunology , Enalapril/administration & dosage , Losartan/administration & dosage , Erythrocyte Volume/drug effects , Glomerulonephritis, IGA/complications , Hypertension/complications
4.
J. bras. nefrol ; 18(3): 243-247, set. 1996. tab, graf
Article in Portuguese | LILACS | ID: lil-208814

ABSTRACT

Os autores administraram captopril a 21 pacientes transplantados de rim, com funçäo renal normal e eritrocitose (hematócrito > 50 por cento e hemoglobina > 16,3 g/dl) e a 12 pacientes igualmente transplantados de rim, com funçäo renal normal e sem eritrocitose. Após 2 meses de tratamento, houve queda estatisticamente significativa do hematócrito (56,1 + 3,9 para 47,8 + 3,6 por cento; p<0,0001) e da hemoglobina (18,2 + 1,3 para 15,4 + 1,3 g/dl; p<0,0001) no grupo com eritrocitose; a manutençäo da terapia näo provocou anemia neste grupo. A interrupçäo em 4 pacientes provocou recorrência da eritrocitose, havendo resposta favorável após a reintroduçäo do captopril. No grupo normoglobúlico näo houve queda significativa dos níveis de hematócrito (43,0 + 3,8 para 43,1 + 4,4 g/dl; p=0,8944) e de hemoglobina (13,6 + 1,3 para 13,6 + 1,4 por cento; p=0,9311). Os pacientes que necessitaram manter a terapia com captopril por tempo mais prolongado näo apresentaram anemia. Concluímos que o uso de captopril constitui terapia eficaz, segura e livre de efeitos colaterais para a eritrocitose pós-transplante renal. Por outro lado, seu uso em pacientes normoglobúlicos näo provoca anemia.


Subject(s)
Humans , Adult , Polycythemia/drug therapy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Captopril/therapeutic use , Kidney Transplantation , Hemoglobins/analysis , Hematocrit
7.
Arch. med. interna (Montevideo) ; 15(1): 1-21, mar. 1993. ilus
Article in Spanish | LILACS | ID: lil-167001

ABSTRACT

La policitemia vera es una enfermedad hematológica maligna clonal, cuyo mayor riesgo es la trombosis vascular. Este artículo considera los progresos existentes en la comprensión de la reología sanguínea, patogenia, clínica, diagnóstico y tratamiento de esta entidad


Subject(s)
Humans , Polycythemia Vera , Rheology , Bloodletting , Polycythemia/blood , Polycythemia/complications , Polycythemia/diagnosis , Polycythemia/drug therapy , Polycythemia/etiology , Polycythemia/physiopathology , Polycythemia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL